Sam Chun Dang Pharm (000250.KQ) Research Hub

Sam Chun Dang Pharm (000250.KQ) trades on KOE, KR in the Healthcare (Medical - Pharmaceuticals) sector. As of 2026-11-05, shares last closed at 176,600 KRW (+0.46%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 378.19, market cap 3576.66B. This hub links to the full technical, earnings and options research available for 000250.KQ.

Last updated 2026-11-05 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Medical - Pharmaceuticals)
ExchangeKOE, KR
Last close176,600 KRW (+0.46%)
52-week range120,000 KRW – 294,000 KRW
Trend regimeRange
14-day RSI30.8 (Bearish)
Trailing P/E378.19
Market cap3576.66B
Dividend yield0.03%

Available research for 000250.KQ

Earnings

000250.KQ earnings date and last-quarter result: P/E 378.19. Updated 2026-07-23.

Options: Covered Call

Covered Call on 000250.KQ: how it works, illustrative setup around the real 176,600 KRW price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on 000250.KQ: how it works, illustrative setup around the real 176,600 KRW price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on 000250.KQ: how it works, illustrative setup around the real 176,600 KRW price, max profit/loss, breakeven and when to use it. Educational.

Technical

000250.KQ technical analysis: range, last 176,600 KRW, RSI 30.8, 52w range 120,000 KRW–294,000 KRW, real support/resistance. Updated 2026-11-05.

More on SniperIQ

Frequently asked questions

What sector is 000250.KQ in?

Sam Chun Dang Pharm (000250.KQ) is classified under Healthcare (Medical - Pharmaceuticals), listed on KOE, KR.

Is 000250.KQ in an uptrend or downtrend?

As of 2026-11-05, 000250.KQ is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is 000250.KQ's trailing P/E ratio?

000250.KQ's trailing P/E is 378.19, with a market cap of 3576.66B. See the earnings research page for full valuation detail.